Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Effectiveness (Immunogenicity) and Safety of GC1107 Administered Intramuscularly in Healthy Adults

Trial Profile

Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Effectiveness (Immunogenicity) and Safety of GC1107 Administered Intramuscularly in Healthy Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2015

At a glance

  • Drugs GC 1107 (Primary) ; Diphtheria-tetanus vaccine
  • Indications Diphtheria; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Green Cross
  • Most Recent Events

    • 17 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top